These studies reveal the therapeutic potential of applying a small molecule inhibitor (PFI-3) of the BRG1 and BRM subunits of SWI/SNF to improve the clinical outcome in GBM using standard-of-care chemotherapy. This evidence concerns the gene SMARCA1 and glioblastoma.